푸드나무, 김우주 체제 전면화…바이오 신사업 시험대

The restructuring of Foodnamoo's management under Kim Woo-joo raises sustainability concerns given the company's ongoing losses and its majority stake acquired entirely through borrowed funds using the shares themselves as collateral. The critical test is whether Foodnamoo's ambitious pivot into biotech, including gene therapy development, can generate sufficient returns to service debt and stabilize operations. Stock performance and execution on new biotech initiatives will determine not only company viability but also whether Kim's management control remains stable.